Nov 2023 $1 M Private placement after listing Under $2 million 2
Heart Test Laboratories, Inc.: Private sale, Nov 2023 × Investors in this round 2 investors had bought by the notice of Dec 7, 2023: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Heart Test Laboratories, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Texas People named in the notice Andrew Simpson · Executive Officer, Director · Andrew Simpson is the President, Chief Executive Officer and Chairman of the Board of Directors. Danielle Watson · Executive Officer · Danielle Watson is the Chief Financial Officer and Treasurer. Mark Hilz · Executive Officer, Director · Mark Hilz is the Chief Operating Officer, Secretary and Director. Brian R. Szymczak · Director Bruce Bent · Director David R. Wells · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Represents 3,125,000 shares of common stock issued to a noteholder to pay off $500,000 drawn from a note and 3,656,388 shares of common stock issued to a noteholder to pay off principal and interest under a loan agreement.”On the use of proceeds: “Some proceeds to be used for general working capital purposes may include salaries, payments and expenses reimbursements to officers and/or directors listed above in Item 3.”Signed by Andrew Simpson, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 7, 2023. Read the notice at the SEC .
equity, debt, options SEC Sep 2023 $1 M Private placement after listing Under $2 million 1
Heart Test Laboratories, Inc.: Private sale, Sep 2023 × Investors in this round 1 investor had bought by the notice of Sep 20, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Heart Test Laboratories, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Texas People named in the notice Andrew Simpson · Executive Officer, Director · Andrew Simpson is the President, Chief Executive Officer and Chairman of the Board of Directors Danielle Watson · Executive Officer · Danielle Watson is the Chief Financial Officer and Treasurer. Mark Hilz · Executive Officer, Director · Mark Hilz is the Chief Operating Officer, Secretary and Director. Brian R. Szymczak · Director Bruce Bent · Director David R. Wells · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Represents the issuance of an unsecured promissory drawdown loan note of up to $1,000,000 and related issuance of up to 1,500,000 warrants, pursuant to the terms of such note and warrants.”On the use of proceeds: “Some proceeds to be used for general working capital purposes may include salaries, payments and expenses reimbursements to officers and/or directors listed above in Item 3.”Signed by Andrew Simpson, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 20, 2023. Read the notice at the SEC .
debt, options SEC Apr 2019 $6 M No. 3 $2 to $10 million 50
Heart Test Laboratories, Inc.: Raise no. 3, Apr 2019 × Investors in this round 50 investors had bought by the notice of Dec 11, 2019: 50 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Heart Test Laboratories, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $6 M of $7 M offered; $0 M still to sell
Smallest investment taken $1,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions none
Finders' fees none
Paid to its own people $400,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Texas People named in the notice Andrew Simpson · Executive Officer Mark Hilz · Executive Officer Brian Szymczak · Director John Adams · Director John Owen · Director Patrick Kanouff · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mark Hilz, President/CEO. Source: SEC Form D, newest notice filed Dec 11, 2019. Read the notice at the SEC .
equity SEC Dec 2014 $4 M No. 2 $2 to $10 million 32
Heart Test Laboratories, Inc.: Raise no. 2, Dec 2014 × Investors in this round 32 investors had bought by the notice of Jul 17, 2015: 32 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Heart Test Laboratories, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $10 M offered; $6 M still to sell
Smallest investment taken $5,000
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $70,000
Finders' fees none
Paid to its own people $300,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Texas People named in the notice Mark Thomas Hilz · Executive Officer Andrew Christopher Simpson · Director Drew Christopher Diaz · Director Kavy Christopher Jeffrey · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Middlebury Securities (CRD 122602) · broker-dealer James Robinson (CRD 1651804) · Weyrbridge Rd, Vermont Sold in NY, PA, TX Neidiger Tucker Bruner (CRD 7425) · broker-dealer Paul Davis (CRD 1630803) · Englewood, Colorado Sold in CO, TX Remarks in the notice On the amounts: “The offering closed in March. No further securities will be offered as part of this offering”On the use of proceeds: “This is total estimated salaries for Mark Hilz and Andrew Simpson for the year 2015 at a rate of $150k per person.”Signed by Mark T. Hilz, President/CEO. Source: SEC Form D, newest notice filed Jul 17, 2015. Read the notice at the SEC .
equity, options SEC Mar 2009 $2 M No. 1 Under $2 million 17
Heart Test Laboratories, Inc.: Raise no. 1, Mar 2009 × Investors in this round 17 investors had bought by the notice of Jul 30, 2009: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 3 investors are named for Heart Test Laboratories, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered; $0 M still to sell
Smallest investment taken $25,000
What was sold equity
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions $160,000
Finders' fees none
Paid to its own people $175,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Texas People named in the notice Drew Diaz · Executive Officer, Director, Promoter Gary Chen · Executive Officer, Director, Promoter Cheryl Yang · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Niderger Tucker Bruner (CRD 7425) · Denver, Co Sold in no state named Remarks in the notice On the use of proceeds: “Salary for the Issuer's officers from June 1009 through December 31, 2009”Signed by Drew Diaz, Chief Excutive Officer. Source: SEC Form D, newest notice filed Jul 30, 2009. Read the notice at the SEC .
equity SEC